Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs———————Recherche et développement———————Résultat d'exploitation———————Total des produits hors exploitation———————Charges d'intérêts, nettes des intérêts capitalisés———————Résultat hors exploitation, hors charges d'intérêts———————Revenus/dépenses exceptionnels———————Résultat avant impôts———————Part des actionnaires dans le résultat———————Impôts———————Intérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts———————Résultat net avant activités abandonnées———————Activités abandonnées———————Résultat net———————Ajustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires———————Bénéfice par action de base (BPA de base)———————Bénéfice par action dilué (BPA dilué)———————Nombre moyen d'actions de base en circulation———————Nombre d'actions en circulation après dilution———————EBITDA———————EBIT———————Coût des ventes———————Autres coûts des ventes———————Amortissements (flux de trésorerie)———————
GSK plc American Depositary Shares (Each representing two Ordin
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost.